|
|
Article: Clinic Roundup.
- Article from:
- BIOWORLD Today
- Article date:
- November 3, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
o Actelion Ltd., of Allschwil, Switzerland, reported a preliminary analysis of its 413-patient, Phase IIb dose-finding study showing that its intravenous clazosentan reached statistical significance vs. placebo at all three doses tested - 15 mg/hour, 5 mg/hour and 1 mg/hour. All met the primary endpoint of reducing the occurrence of moderate or severe cerebral vasospasm, as measured by cerebral angiography at day nine post-aneurysm rupture compared to placebo. However, results also showed a lack of clinical benefit in patients who had experienced subarachnoid hemorrhage, and that news dropped Actelion's stock by more than 12 percent Monday. Treatment with clazosentan, an ...